Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
STRO Sutro Biopharma Inc
- Stocks
- Healthcare
- NASDAQ: STRO
Price (delayed)
$0.9094
Market cap
$76.81M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.98
Enterprise value
-$8.88M
Sutro Biopharma, Inc., located in South San Francisco, is a clinical-stage drug discovery, development and manufacturing company. Using precise protein engineering and rational design, Sutro is advancing next-generation oncology therapeutics.
Highlights
The company's debt fell by 24% YoY and by 8% QoQ
Sutro Biopharma's revenue has shrunk by 57% YoY but it has increased by 7% QoQ
The gross profit has plunged by 57% YoY but it has grown by 7% from the previous quarter
The equity has dropped by 158% since the previous quarter and by 126% year-on-year
STRO's net income has plunged by 113% YoY and by 8% from the previous quarter
Key stats
What are the main financial stats of STRO
Market
Valuations
Earnings
Shares outstanding
84.46M
Market cap
$76.81M
Enterprise value
-$8.88M
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
1.14
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-0.13
Revenue
$66.43M
Gross profit
$66.43M
Operating income
-$250.38M
Net income
-$245.22M
EBIT
-$218.53M
EBITDA
-$205.86M
Free cash flow
-$198.51M
Per share
Balance sheet
Liquidity
EPS
-$2.98
EPS diluted
-$2.98
Free cash flow per share
-$2.39
Book value per share
-$0.31
Revenue per share
$0.8
TBVPS
$3.87
Total assets
$321.43M
Total liabilities
$347.24M
Debt
$21.4M
Equity
-$25.81M
Working capital
$154.36M
Debt to equity
-0.83
Current ratio
2.16
Quick ratio
1.98
Net debt/EBITDA
0.42
Margins
Efficiency
Dividend
EBITDA margin
-309.9%
Gross margin
100%
Net margin
-369.1%
Operating margin
-376.9%
Return on assets
-59.5%
Return on equity
-347.6%
Return on invested capital
-133.7%
Return on capital employed
-116%
Return on sales
-328.9%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
STRO stock price
How has the Sutro Biopharma stock price performed over time
Intraday
-0.43%
1 week
-0.69%
1 month
-17.33%
1 year
-77.15%
YTD
-50.58%
QTD
39.78%
Financial performance
How have Sutro Biopharma's revenue and profit performed over time
Revenue
$66.43M
Gross profit
$66.43M
Operating income
-$250.38M
Net income
-$245.22M
Gross margin
100%
Net margin
-369.1%
STRO's operating income has dropped by 142% year-on-year and by 5% since the previous quarter
STRO's net income has plunged by 113% YoY and by 8% from the previous quarter
Sutro Biopharma's revenue has shrunk by 57% YoY but it has increased by 7% QoQ
The gross profit has plunged by 57% YoY but it has grown by 7% from the previous quarter
Price vs fundamentals
How does STRO's price correlate with its fundamentals
Growth
What is Sutro Biopharma's growth rate over time
Valuation
What is Sutro Biopharma stock price valuation
P/E
N/A
P/B
N/A
P/S
1.14
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-0.13
STRO's EPS has plunged by 59% YoY
The equity has dropped by 158% since the previous quarter and by 126% year-on-year
The stock's price to sales (P/S) is 83% less than its 5-year quarterly average of 6.7 and 29% less than its last 4 quarters average of 1.6
Sutro Biopharma's revenue has shrunk by 57% YoY but it has increased by 7% QoQ
Efficiency
How efficient is Sutro Biopharma business performance
STRO's return on assets has dropped by 129% year-on-year and by 13% since the previous quarter
Sutro Biopharma's ROE has plunged by 55% from the previous quarter
STRO's return on invested capital is down by 40% since the previous quarter
STRO's ROS is down by 2.4% from the previous quarter
Dividends
What is STRO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for STRO.
Financial health
How did Sutro Biopharma financials performed over time
STRO's total assets is 7% smaller than its total liabilities
The quick ratio has plunged by 54% YoY and by 20% from the previous quarter
Sutro Biopharma's current ratio has plunged by 52% YoY and by 17% from the previous quarter
The company's debt is 183% higher than its equity
The equity has dropped by 158% since the previous quarter and by 126% year-on-year
The company's debt fell by 24% YoY and by 8% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.